dr. o’donnell on the evolution of immunotherapy in metastatic bladder cancer
Published 5 years ago • 228 plays • Length 2:07Download video MP4
Download video MP3
Similar videos
-
0:54
dr. o’donnell on challenges with pd-l1 testing in bladder cancer
-
1:12
dr. o’donnell on ongoing immunotherapy trials in bladder cancer
-
1:21
dr. o’donnell on pd-l1 testing in bladder cancer
-
1:06
dr. o'donnell compares checkpoint inhibitors in bladder cancer
-
4:43
the evolution of immunotherapy in cancer
-
2:50
a therapeutic revolution: immunotherapy for bladder cancer
-
26:56
bladder cancer immunotherapy: building on a history of immune response
-
15:15
the role of immunotherapy in metastatic bladder cancer
-
2:03
the evolution of bladder cancer treatment and the immuno-oncology era
-
4:17
metastatic bladder cancer: progression after maintenance
-
5:19
bladder cancer: real-world experience with immunotherapy
-
1:03
dr. peter o’donnell on atezolizumab and imvigor 210
-
1:03
dr. inman discusses the biology of bladder cancer
-
1:55
dr. o'neil on standard of care in muscle-invasive bladder cancer
-
9:56
historic perspective on treatment of bladder cancer
-
2:06
dr. bellmunt highlights immunotherapy options in bladder cancer
-
3:41
impact of immunotherapy in advanced bladder cancer
-
4:46
changing the standard of care in metastatic bladder cancer
-
2:50
the evolution of pd-l1 immunotherapy for bladder cancer